Product Name:N-Boc-piperazine

IUPAC Name:tert-butyl piperazine-1-carboxylate

CAS:57260-71-6
Molecular Formula:C9H18N2O2
Purity:98%
Catalog Number:CM103943
Molecular Weight:186.26

Packing Unit Available Stock Price($) Quantity
CM103943-500g in stock ƥŞ
CM103943-1000g in stock ȅȯȯ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:57260-71-6
Molecular Formula:C9H18N2O2
Melting Point:-
Smiles Code:CC(C)(C)OC(=O)N1CCNCC1
Density:
Catalog Number:CM103943
Molecular Weight:186.26
Boiling Point:
MDL No:MFCD00075265
Storage:

Category Infos

PROTAC-Linkers
PROTACs (Proteolytic Targeting Chimeric Molecules) are heterobifunctional protein degraders and are promising targeted therapy candidates for cancer. PROTAC is composed of three parts, one end is connected with the ligand bound by E3 ligase, the other end is connected with the ligand bound by the target protein, and the middle is the linker.
Protac Linkers
where to buy PROTAC-Linkers, Chemenu is research-based manufacturer of pharmaceutical intermediates. We supply Protac Linkers with low price.Warmly welcome new and old customers to visit!

Column Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Avapritinib
Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.  AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.